Hanmi Science (KOSE:A008930) - Share price, News & Analysis

A008930 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	5/6
Financial Health	5/6
Dividends	0/6

A008930 Stock Overview

Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally.

Rewards

Earnings grew by 90% over the past year

Risk Analysis

No risks detected for A008930 from our risk checks.

Hanmi Science Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hanmi Science
Historical stock prices
Current Share Price	₩49,500.00
52 Week High	₩91,862.75
52 Week Low	₩40,950.00
Beta	1.3
1 Month Change	1.02%
3 Month Change	2.48%
1 Year Change	-25.53%
3 Year Change	-23.98%
5 Year Change	-21.81%
Change since IPO	10,405.31%

Recent News & Updates

Apr 29

Is Hanmi Science (KRX:008930) Using Too Much Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Shareholder Returns

	A008930	KR Pharmaceuticals	KR Market
7D	5.1%	1.7%	1.2%
1Y	-25.5%	-24.5%	-14.3%

Return vs Industry: A008930 exceeded the KR Pharmaceuticals industry which returned -26.6% over the past year.

Return vs Market: A008930 underperformed the KR Market which returned -14.2% over the past year.

Price Volatility

Is A008930's price volatile compared to industry and market?
A008930 volatility
A008930 Average Weekly Movement	5.7%
Pharmaceuticals Industry Average Movement	4.2%
Market Average Movement	5.4%
10% most volatile stocks in KR Market	10.2%
10% least volatile stocks in KR Market	3.1%

Stable Share Price: A008930 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: A008930's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1973	86	Lim Chong-Yoon	https://www.hanmiscience.co.kr

Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer. The company also offers drug substances, general medicines, health functional foods, and nutrition and health products and services.

Hanmi Science Fundamentals Summary

How do Hanmi Science's earnings and revenue compare to its market cap?
A008930 fundamental statistics
Market Cap	₩3.33t
Earnings (TTM)	₩42.94b
Revenue (TTM)	₩950.16b

77.5x

P/E Ratio

3.5x

P/S Ratio

Is A008930 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
A008930 income statement (TTM)
Revenue	₩950.16b
Cost of Revenue	₩819.07b
Gross Profit	₩131.10b
Other Expenses	₩88.16b
Earnings	₩42.94b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	638.58
Gross Margin	13.80%
Net Profit Margin	4.52%
Debt/Equity Ratio	8.0%

How did A008930 perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

31%

Payout Ratio

Valuation

Is Hanmi Science undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

77.52x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: A008930 (₩49500) is trading above our estimate of fair value (₩4137.24)

Significantly Below Fair Value: A008930 is trading above our estimate of fair value.

Price To Earnings Ratio

PE vs Industry: A008930 is poor value based on its PE Ratio (77.5x) compared to the KR Pharmaceuticals industry average (25.6x).

PE vs Market: A008930 is poor value based on its PE Ratio (77.5x) compared to the KR market (14x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate A008930's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: A008930 is overvalued based on its PB Ratio (4.8x) compared to the KR Pharmaceuticals industry average (1.6x).

Future Growth

How is Hanmi Science forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

19.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hanmi Science has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Hanmi Science performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

29.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: A008930 has high quality earnings.

Growing Profit Margin: A008930's current net profit margins (4.5%) are higher than last year (2.6%).

Past Earnings Growth Analysis

Earnings Trend: A008930's earnings have grown significantly by 29.5% per year over the past 5 years.

Accelerating Growth: A008930's earnings growth over the past year (90%) exceeds its 5-year average (29.5% per year).

Earnings vs Industry: A008930 earnings growth over the past year (90%) exceeded the Pharmaceuticals industry -10.9%.

Return on Equity

High ROE: A008930's Return on Equity (6.2%) is considered low.

Financial Health

How is Hanmi Science's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: A008930's short term assets (₩222.6B) exceed its short term liabilities (₩221.0B).

Long Term Liabilities: A008930's short term assets (₩222.6B) exceed its long term liabilities (₩38.6B).

Debt to Equity History and Analysis

Debt Level: A008930's net debt to equity ratio (5.6%) is considered satisfactory.

Reducing Debt: A008930's debt to equity ratio has increased from 3.9% to 8% over the past 5 years.

Debt Coverage: A008930's debt is well covered by operating cash flow (24.9%).

Interest Coverage: A008930's interest payments on its debt are well covered by EBIT (16.9x coverage).

Balance Sheet

Dividend

What is Hanmi Science current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

0.40%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: A008930's dividend (0.4%) isn’t notable compared to the bottom 25% of dividend payers in the KR market (0.85%).

High Dividend: A008930's dividend (0.4%) is low compared to the top 25% of dividend payers in the KR market (2.75%).

Stability and Growth of Payments

Stable Dividend: A008930 is not paying a notable dividend for the KR market, therefore no need to check if payments are stable.

Growing Dividend: A008930 is not paying a notable dividend for the KR market, therefore no need to check if payments are increasing.

Earnings Payout to Shareholders

Earnings Coverage: A008930 is not paying a notable dividend for the KR market.

Cash Payout to Shareholders

Cash Flow Coverage: A008930 is not paying a notable dividend for the KR market.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

CEO

Lim Chong-Yoon (49 yo)

no data

Tenure

Mr. Lim Chong-Yoon serves as President of Business Development at Hanmi Pharm. Co., Ltd and serves as its Executive Director. Mr. Lim serves as the Chief Executive Officer and President of Hanmi Science Co...

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/23 00:00
End of Day Share Price	2022/05/23 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31